Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$21.01 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.86M

Average 2.11M

BEAM Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Beam Therapeutics Inc.NASDAQ: BEAM

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development dips below year-ago levels

Q2 FY2026 research & development of $95.1M fell 6.5% year over year, behind the +3.1% change in trailing-twelve-month research & development. Sequentially, it fell 9.0% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.

Context

  • Research & development amounted to 293.1% of revenue in FY2025, down 285.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -6.5% toward the trailing-twelve-month pace of +3.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$95.1M-9.0% QoQ
Last fiscal yearDec 2025
$409.62M+11.4% YoY
LTMJun 2026
$408.66M+3.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.5%——
1 year+11.4%——
3-year CAGR+9.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
409.62M USD
Year-over-year change
+11.4%
4-year CAGR
+1.4%

Research & Development vs competitors

How BEAM compares with its peers on the latest reported figures

  • BEAM's LTM Jun 2026 research & development of $408.66M is the highest of the 9 companies compared; the peer median is $97.58M.
  • Its year-over-year change of +3.1% is the 2nd highest of 9, against a peer median of -22.7%.
  • Research & development amounts to 261.9% of revenue for BEAM, versus a peer median of 546.5%.
BEAM Competitors Peer median
Research & Development for BEAM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BEAMBeam Therapeutics Inc.LTM Jun 2026$408.66M +3.1%+9.5%261.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M -21.5%-2.5%546.5%
CRSPCRISPR Therapeutics AGLTM Sep 2026$283.28M +1.6%-16.9%1125.4%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M -32.1%-16.3%—
FATEFate Therapeutics, Inc.LTM Mar 2026$100.48M -23.9%-30.4%1590.8%
CLLSCellectis S.A.LTM Mar 2026$94.68M +5.0%-1.4%139.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M -28.3%+10.0%843.7%
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M -62.3%-19.9%171.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$53.36M -10.8%+5.5%118.4%
Peer median (excluding BEAM) $97.58M-22.7%-9.4%546.5%

Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue51.84M60.92M377.71M63.52M139.74M
Cost of Revenue232.13M311.59M0367.56M22.29M
Gross Profit(180.29M)(250.67M)377.71M(304.04M)117.45M
Gross Margin-347.8%-411.5%100.0%-478.7%84.0%
Research & Development387.09M311.59M437.38M367.56M409.62M
Selling, General & Admin57.22M87.81M116.81M111.53M113.82M
Operating Expenses212.18M87.81M554.19M111.53M501.14M
Depreciation & Amortization7.45M14.15M20.01M21.93M22.29M
EBITDA(230.06M)(271.53M)(111.15M)(354.78M)(13.97M)
EBITDA Margin-443.8%-445.7%-29.4%-558.5%-10.0%
Operating Income(392.47M)(338.48M)(176.49M)(415.57M)(383.69M)
Operating Margin-757.0%-555.6%-46.7%-654.3%-274.6%
Interest Income015.3M46.68M49.09M0
Interest Expense000043.73M
Other Income / Expenses21.83M52.8M45.32M38.87M303.7M
Income Before Tax(370.64M)(285.68M)(131.16M)(376.7M)(79.99M)
Pre-Tax Margin-714.9%-468.9%-34.7%-593.1%-57.2%
Income Tax Expense03.41M1.37M39K0
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)
Net Margin-714.9%-474.5%-35.1%-593.1%-57.2%
EPS (Basic)(5.77)(4.13)(1.72)(4.58)(0.81)
EPS (Diluted)(5.77)(4.13)(1.72)(4.58)(0.81)
Weighted Avg Shares64.23M70.02M77.15M82.31M98.91M
Weighted Avg Shares (Diluted)64.23M70.02M77.15M82.31M98.91M

Beam Therapeutics Inc.

NASDAQ:BEAM

Intrinsic Alpha fair value

Locked

Current Price

$21.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.